Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole

Jacqueline M. Lafky, André T. Baron, Elsa M. Cora, David W. Hillman, Vera Jean Suman, Edith A. Perez, James N. Ingle, Nita J. Maihale

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Previous studies have implicated estrogen as a regulator of epidermal growth factor receptor (EGFR) expression in breast tumors. We therefore speculated that estrogen might modulate serologic soluble EGFR (sEGFR) concentrations in breast cancer patients. Accordingly, we measured serum sEGFR concentrations in postmenopausal women with metastatic breast cancer (MBC) treated with letrozole, an aromatase inhibitor that blocks estrogen synthesis. Serum specimens were obtained prior to and following 1 and 3 months of letrozole therapy. We report that sEGFR concentrations do not differ between MBC patients prior to letrozole treatment and age-and postmenopause-matched healthy women (P = 0.468). In contrast, however, sEGFR concentrations decreased significantly in 76% of MBC patients after both 1 month (P = 0.006) and 3 months (P = 0.003) of letrozole therapy versus pretreatment concentrations. Within the limitations of this study, we found no evidence for an association between pretreatment sEGFR concentrations or decreased treatment sEGFR concentrations and either progression-free or overall survival. Nonetheless, we conclude that future prospective studies are warranted to determine if baseline and/or longitudinal serum sEGFR concentrations may be useful for predicting disease progression and survival, and/or for monitoring responsiveness to aromatase inhibitors or other endocrine therapies in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)3059-3062
Number of pages4
JournalCancer Research
Volume65
Issue number8
StatePublished - Apr 15 2005

Fingerprint

letrozole
Epidermal Growth Factor Receptor
Breast Neoplasms
Serum
Aromatase Inhibitors
Estrogens
Postmenopause
Therapeutics
Survival
Disease Progression
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lafky, J. M., Baron, A. T., Cora, E. M., Hillman, D. W., Suman, V. J., Perez, E. A., ... Maihale, N. J. (2005). Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. Cancer Research, 65(8), 3059-3062.

Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. / Lafky, Jacqueline M.; Baron, André T.; Cora, Elsa M.; Hillman, David W.; Suman, Vera Jean; Perez, Edith A.; Ingle, James N.; Maihale, Nita J.

In: Cancer Research, Vol. 65, No. 8, 15.04.2005, p. 3059-3062.

Research output: Contribution to journalArticle

Lafky, JM, Baron, AT, Cora, EM, Hillman, DW, Suman, VJ, Perez, EA, Ingle, JN & Maihale, NJ 2005, 'Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole', Cancer Research, vol. 65, no. 8, pp. 3059-3062.
Lafky, Jacqueline M. ; Baron, André T. ; Cora, Elsa M. ; Hillman, David W. ; Suman, Vera Jean ; Perez, Edith A. ; Ingle, James N. ; Maihale, Nita J. / Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole. In: Cancer Research. 2005 ; Vol. 65, No. 8. pp. 3059-3062.
@article{06d31637bba74c6ea78dbefefc3b86cd,
title = "Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole",
abstract = "Previous studies have implicated estrogen as a regulator of epidermal growth factor receptor (EGFR) expression in breast tumors. We therefore speculated that estrogen might modulate serologic soluble EGFR (sEGFR) concentrations in breast cancer patients. Accordingly, we measured serum sEGFR concentrations in postmenopausal women with metastatic breast cancer (MBC) treated with letrozole, an aromatase inhibitor that blocks estrogen synthesis. Serum specimens were obtained prior to and following 1 and 3 months of letrozole therapy. We report that sEGFR concentrations do not differ between MBC patients prior to letrozole treatment and age-and postmenopause-matched healthy women (P = 0.468). In contrast, however, sEGFR concentrations decreased significantly in 76{\%} of MBC patients after both 1 month (P = 0.006) and 3 months (P = 0.003) of letrozole therapy versus pretreatment concentrations. Within the limitations of this study, we found no evidence for an association between pretreatment sEGFR concentrations or decreased treatment sEGFR concentrations and either progression-free or overall survival. Nonetheless, we conclude that future prospective studies are warranted to determine if baseline and/or longitudinal serum sEGFR concentrations may be useful for predicting disease progression and survival, and/or for monitoring responsiveness to aromatase inhibitors or other endocrine therapies in breast cancer patients.",
author = "Lafky, {Jacqueline M.} and Baron, {Andr{\'e} T.} and Cora, {Elsa M.} and Hillman, {David W.} and Suman, {Vera Jean} and Perez, {Edith A.} and Ingle, {James N.} and Maihale, {Nita J.}",
year = "2005",
month = "4",
day = "15",
language = "English (US)",
volume = "65",
pages = "3059--3062",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole

AU - Lafky, Jacqueline M.

AU - Baron, André T.

AU - Cora, Elsa M.

AU - Hillman, David W.

AU - Suman, Vera Jean

AU - Perez, Edith A.

AU - Ingle, James N.

AU - Maihale, Nita J.

PY - 2005/4/15

Y1 - 2005/4/15

N2 - Previous studies have implicated estrogen as a regulator of epidermal growth factor receptor (EGFR) expression in breast tumors. We therefore speculated that estrogen might modulate serologic soluble EGFR (sEGFR) concentrations in breast cancer patients. Accordingly, we measured serum sEGFR concentrations in postmenopausal women with metastatic breast cancer (MBC) treated with letrozole, an aromatase inhibitor that blocks estrogen synthesis. Serum specimens were obtained prior to and following 1 and 3 months of letrozole therapy. We report that sEGFR concentrations do not differ between MBC patients prior to letrozole treatment and age-and postmenopause-matched healthy women (P = 0.468). In contrast, however, sEGFR concentrations decreased significantly in 76% of MBC patients after both 1 month (P = 0.006) and 3 months (P = 0.003) of letrozole therapy versus pretreatment concentrations. Within the limitations of this study, we found no evidence for an association between pretreatment sEGFR concentrations or decreased treatment sEGFR concentrations and either progression-free or overall survival. Nonetheless, we conclude that future prospective studies are warranted to determine if baseline and/or longitudinal serum sEGFR concentrations may be useful for predicting disease progression and survival, and/or for monitoring responsiveness to aromatase inhibitors or other endocrine therapies in breast cancer patients.

AB - Previous studies have implicated estrogen as a regulator of epidermal growth factor receptor (EGFR) expression in breast tumors. We therefore speculated that estrogen might modulate serologic soluble EGFR (sEGFR) concentrations in breast cancer patients. Accordingly, we measured serum sEGFR concentrations in postmenopausal women with metastatic breast cancer (MBC) treated with letrozole, an aromatase inhibitor that blocks estrogen synthesis. Serum specimens were obtained prior to and following 1 and 3 months of letrozole therapy. We report that sEGFR concentrations do not differ between MBC patients prior to letrozole treatment and age-and postmenopause-matched healthy women (P = 0.468). In contrast, however, sEGFR concentrations decreased significantly in 76% of MBC patients after both 1 month (P = 0.006) and 3 months (P = 0.003) of letrozole therapy versus pretreatment concentrations. Within the limitations of this study, we found no evidence for an association between pretreatment sEGFR concentrations or decreased treatment sEGFR concentrations and either progression-free or overall survival. Nonetheless, we conclude that future prospective studies are warranted to determine if baseline and/or longitudinal serum sEGFR concentrations may be useful for predicting disease progression and survival, and/or for monitoring responsiveness to aromatase inhibitors or other endocrine therapies in breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=17144392602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144392602&partnerID=8YFLogxK

M3 - Article

C2 - 15833834

AN - SCOPUS:17144392602

VL - 65

SP - 3059

EP - 3062

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -